Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-001078 Act: 34 Size: 11 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000933 Act: 34 Size: 3 MB 网页链接
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-20-000911 Act: 34 Size: 7 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000909 Act: 34 Size: 239 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000872 Act: 34 Size: 129 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000743 Act: 34 Size: 212 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000692 Act: 34 Size: 13 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000687 Act: 34 Size: 4 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000657 Act: 34 Size: 135 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-20-000550 Act: 34 Size: 159 KB 网页链接